AZD3965 is an orally bioavailable MCT1 inhibitor in phase I clinical trials that effectively increases T cell infiltration, reduces lactate efflux from tumor cells, and reverses the immunosuppressive microenvironment of solid tumors (234). This evidence concerns the gene SLC16A1 and neoplasm.